Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jian Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6558-791X; OpenAlex author ID A5100409987. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers

Papers 16

  1. Development and validation of a CT-based radiomics model to predict survival-graded fibrosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/js9.0000000000002059↗
  2. Hsa_circ_0058495-mediated IGF2BP2 ubiquitination and m6A modification of MEKK1 promote the progression of PDAC. First author DOI 10.7150/thno.117202↗
  3. Discovery of a potent and highly selective inhibitor of SIRT6 against pancreatic cancer metastasis in vivo. Last author DOI 10.1016/j.apsb.2023.11.014↗
  4. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216607↗
  5. Development and validation of a deep learning radiomics model with clinical-radiological characteristics for the identification of occult peritoneal metastases… Co-author DOI 10.1097/js9.0000000000001213↗
  6. Pancreatic Cancer and its Attributable Risk Factors in East Asia, Now and Future. Co-author DOI 10.1093/oncolo/oyad147↗
  7. Ubiquitin signaling in pancreatic ductal adenocarcinoma. First author DOI 10.3389/fmolb.2023.1304639↗
  8. Transcriptome and Lipidomic Analysis Suggests Lipid Metabolism Reprogramming and Upregulating SPHK1 Promotes Stemness in Pancreatic Ductal Adenocarcinoma Stem-… Co-author DOI 10.3390/metabo13111132↗
  9. Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells. Last author DOI 10.1016/j.apsb.2021.06.015↗
  10. Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41401-022-00897-4↗
  11. Erratum: MiR-216a-5p inhibits tumorigenesis in Pancreatic Cancer by targeting TPT1/mTORC1 and is mediated by LINC01133: Erratum. Co-author DOI 10.7150/ijbs.70911↗
  12. Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells. Co-author DOI 10.1186/s12885-020-07743-y↗
  13. A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Meta… Co-author DOI 10.1158/1055-9965.epi-18-0813↗
  14. Enriched environment housing enhances the sensitivity of mouse pancreatic cancer to chemotherapeutic agents. Co-author DOI 10.1016/j.bbrc.2016.03.128↗
  15. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Co-author DOI 10.5301/tj.5000499↗
  16. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Co-author DOI 10.1007/s12032-015-0580-4↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shengnan Lv · 2 shared papers, 2023–2025 · strength 0.46
  2. Feng Wei · 2 shared papers, 2023–2025 · strength 0.46
  3. Siya Shi · 2 shared papers, 2024–2025 · strength 0.44
  4. Yanji Luo · 2 shared papers, 2024–2025 · strength 0.44
  5. Shi‐Ting Feng · 2 shared papers, 2024–2025 · strength 0.44
  6. Qiufen Zhang · 2 shared papers, 2022–2024 · strength 0.29
  7. Tongjia Chu · 1 shared paper, 2025 · strength 0.24
  8. Jiawei Liu · 1 shared paper, 2025 · strength 0.24
  9. Xinyu Peng · 1 shared paper, 2023 · strength 0.22
  10. Xiaojing Du · 1 shared paper, 2023 · strength 0.19
  11. Jinglin Xia · 1 shared paper, 2023 · strength 0.19
  12. Xin Cao · 1 shared paper, 2023 · strength 0.19
  13. Jin-Zhi Xu · 1 shared paper, 2023 · strength 0.19
  14. Tao Wei · 1 shared paper, 2024 · strength 0.19
  15. Qi Zhang · 1 shared paper, 2024 · strength 0.19
  16. Jianfeng Lü · 1 shared paper, 2024 · strength 0.19
  17. Jin Li · 1 shared paper, 2024 · strength 0.19
  18. Tingbo Liang · 1 shared paper, 2024 · strength 0.19
  19. Kun-Dong Zhang · 1 shared paper, 2022 · strength 0.17
  20. Cheng-xiang Wang · 1 shared paper, 2022 · strength 0.17
  21. Xinyuan Xu · 1 shared paper, 2024 · strength 0.17
  22. Kuiwu Ren · 1 shared paper, 2023 · strength 0.17
  23. Chunlong Liu · 1 shared paper, 2023 · strength 0.17
  24. Panpan Wu · 1 shared paper, 2023 · strength 0.17
  25. Jiangtao Yu · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.